Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human retinal pigment epithelial cell therapy - Astellas Pharma

Drug Profile

Human retinal pigment epithelial cell therapy - Astellas Pharma

Alternative Names: ACT hESC-RPE; ASP7317; hESC-derived RPE; hRPE cell therapy; Human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells - Astellas; MA09-hRPE

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advanced Cell Technology
  • Developer Astellas Institute for Regenerative Medicine; Astellas Pharma; CHA Bio & Diostech
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Stargardt disease
  • Phase I/II Age-related macular degeneration; Macular degeneration
  • No development reported Degenerative myopia

Most Recent Events

  • 21 Jun 2019 Ocata Therapeutics completes a phase I/II trial for Stargardt disease in USA (NCT02445612)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Stargardt disease 1 in South Korea (Intraocular, Injection)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Degenerative myopia in USA (Intraocular, Injection)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top